COMPANY
SUNGJIN, leading globalization of the pharmaceutical industry
History
History
2021
  • Acquired Product license of all DFE Pharma products
2020
  • Won 'Best DC Revenue Growth' awards from DFE Pharma
2019
  • Awarded Appreciation plaque from JW Pharmaceutical
  • SungJin's 40th company anniversary
2017
  • Moved to the new office building (SungJin building)
2015
  • Constructed SungJin’s new office building
2012
  • Started exporting Potassium Clavulanate API of Shandong Newtime Pharmaceutical Co.,Ltd
    (Lunan Pharmaceutical Group) (China) to Deva Holding A.S.
2010
  • Initiated business with Shandong Newtime
    Pharmaceutical Co.,Ltd (Lunan Pharmaceutical Group) (China)
2009
  • Obtained KGSP qualification as a pharmaceutical wholesaler
2005
  • Expanded the domestic market for by anticancer
    drugs conducting exclusive business in Korea with
    Heraeus Deutschland GmbH & Co. KG (Germany)
2003
  • Signed an exclusive agency agreement
    with Procos S.p.A (Italy)
  • Initiated business with IPCA Laboratories Ltd. (India)
2002
  • Initiated business with Ind-Swift Laboratories Ltd.
    (India) as an exclusive agent in Korean market
2000
  • Established SUNGJIN GLOBAL CO., LTD.
  • Signed an exclusive agency agreement
    with Newchem S.p.A (Italy)
1999
  • Established a subsidiary company,
    YOUNGWOO INDUSTRIAL
  • Acquired building of Hannara Party
1998
  • Established a local branch office in Beijing, China, to expand
    export business and approval for finished products of Korea
1997
  • Purchased site for SungJin office building
  • Initiated business with Uquifa S.A. (Spain)
1995
  • Initiated business with DEPA (Turkey)
    (=Deva Holding A.S., at present)
1994
  • Changed company name to SUNGJIN [EX-IM] CO., LTD.
    from SungJin Corporation
1993
  • Launched domestic business on Airtal® of Almirall, S.A. (Spain)
1992
  • Moved into Trade Tower in Samsung-dong
1990
  • Launched domestic business on Disgren® of Uriach (Spain)
1989
  • Signed an exclusive agency agreement with DMV-Fonterra Exipients (Netherlands) (=DFE Pharma, at present)
1987
  • Signed an exclusive agency agreement with Frutarom
    (Switzerland) (=IFF Health, at present)
1983
  • Introduced cephalosporin antibiotics into the
    domestic market by signing an exclusive agency
    agreement with ACS DOBFAR S.p.A. (Italy)
1981
  • Introduced penicillin into the domestic market by signing an
    exclusive agency agreement with Novo Nordisk A/S (Denmark)
1979
  • Foundation of SungJin Corporation